Piezowave Therapy for Erectile Dysfunction in 2022

For men with moderate erectile dysfunction (ED), a noninvasive technique called low-intensity shockwave therapy or piezowave therapy leads to significant improvement in sexual function.

Shockwave therapy is highly effective and safe in patients with moderate vasculogenic ED. In a recent study, more than two-thirds of patients undergoing a 6-week course of shockwave therapy treatment had clinically meaningful improvement on a standard rating scale of sexual function and satisfaction.

What is Shockwave Therapy?

The clinical term for this treatment used by urologists is low-intensity shockwave therapy. During the treatment, a small wand-like device (PiezoWave) utilizes targeted sound waves to stimulate penile tissue and encourage blood flow, which can also speed up the healing process.

PiezoWave is a device that is classified as myofascial acoustic compression therapy. It uses low intensity shock waves to target damaged tissue to manipulate and compress tissue. This manipulation increases circulation and blood flow. It can be used for the treatment of Erectile Dysfunction or Peyronies Disease. It is non-invasive, quick, and comfortable.

Shockwaves have also been shown to grow new blood vessels and improve blood flow in the penis — which is essential for erections.

• Data shows it can stimulate blood flow and potentially help grow new blood vessels.
• A licensed medical professional with professional training is required to administer this treatment.
• It is not yet approved by the Food and Drug Administration (FDA) for use in treating erectile dysfunction.

New Study on ED

Low-intensity shock wave therapy shows efficacy over 6 weeks in men with moderate vasculogenic erectile dysfunction (ED), according to new trial findings.

In the latest trial, researchers randomly assigned 70 patients (divided into two groups) to 12 total sessions of low-intensity shockwave therapy twice weekly for 6 weeks. Using the ARIES 2TM device, they applied 5000 impulses at 0.096 mJ/mm2 energy flux density and 5 Hz frequency to the intervention group. All participants had previously shown good or partial response to inhibitors.

At 3 months, a minimal clinically important difference in the International Index of Erectile Function (IIEF-EF) scores was achieved by 79 percent of the shockwave group compared with 0 of the sham group. As reported in the Journal of Urology, lead researcher Dr. Pyrgidis observed a minimal clinically important difference with shock wave therapy at 1 month in 59 percent of the treated group compared with 2.9 percent of the sham group, respectively.